MHRA

Current listing of UK brokers authorised to broker human medicines, including company name, registration and address.

The MHRA register of licensed manufacturing sites: manufacturer specials – human (MS) and manufacturer specials authorisation – veterinary (MANSA) only.

Laboratoires Théa trading as Thea Pharmaceuticals Limited have notified the MHRA of an out of specification event related to environmental monitoring during manufacturing, which may increase the risk of microbial contamination of the medicinal product.

There is a small increase in the risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and Arexvy (GSK RSV vaccine) in adults aged 60 years and older. Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barré syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 July 2025, approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where the disease remains confined to the inner lining of the bladder and may include tumours. 

How to register your medical devices with the MHRA for the markets in Great Britain and Northern Ireland.

Helping manufacturers define the characteristics of their devices and determine the appropriate regulatory qualification and classification.

Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.

The MHRA is consulting with UK stakeholders to gather feedback and comments on a new international guideline for the appropriate inclusion and/or retention of pregnant and/or breast-feeding individuals in clinical trials of medicines.

Information about how we handle potential corporate conflicts of interest (COI) between different parts of the Agency.

Information and recommendations for manufacturers on the preparation and presentation of a periodic safety update report (PSUR).

List of Field Safety Notices from 23 to 27 June 2025.